These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22628142)

  • 1. Methylphenidate in children with ADHD with or without learning disability.
    Williamson D; Murray DW; Damaraju CV; Ascher S; Starr HL
    J Atten Disord; 2014 Feb; 18(2):95-104. PubMed ID: 22628142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of treatment effect of OROS® methylphenidate in children with ADHD.
    Armstrong RB; Damaraju CV; Ascher S; Schwarzman L; O'Neill J; Starr HL
    J Atten Disord; 2012 Nov; 16(8):697-705. PubMed ID: 22084448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
    Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
    J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
    Abikoff H; Nissley-Tsiopinis J; Gallagher R; Zambenedetti M; Seyffert M; Boorady R; McCarthy J
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):166-75. PubMed ID: 19127171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
    Reimherr FW; Williams ED; Strong RE; Mestas R; Soni P; Marchant BK
    J Clin Psychiatry; 2007 Jan; 68(1):93-101. PubMed ID: 17284136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
    Wigal SB; Childress AC; Belden HW; Berry SA
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):3-10. PubMed ID: 23289899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
    Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.
    Findling RL; Bukstein OG; Melmed RD; López FA; Sallee FR; Arnold LE; Pratt RD
    J Clin Psychiatry; 2008 Jan; 69(1):149-59. PubMed ID: 18312050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
    Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM
    J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission.
    Goodman DW; Starr HL; Ma YW; Rostain AL; Ascher S; Armstrong RB
    J Clin Psychiatry; 2017 Jan; 78(1):105-114. PubMed ID: 27487193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.